Givaudan, the worldwide leader in fragrance and beauty, announced an equity spending and strategic partnering with the Swiss organization Microcaps AG to strengthen its encapsulation capabilities, reinforcing its leadership in fragrance innovation and customer-centric services.
Encapsulation technology plays a significant role in improving fragrance performance, allowing longer-lasting scents and enhancing consumer enjoyment in a broad range of fine fragrance, cosmetic and targeted care products. This partnership unites Givaudan's market-leading fragrance formulation expertise with Microcaps' patented advance precision microencapsulation technology, particularly in the region of non-alcoholic fine fragrance performance, creating opportunities to generate high-performing fragrances and cosmetic applications.
"Partnering with Microcaps is a strategic step that further strengthens our innovation capabilities. Together, we will continue to deliver superior fragrance experiences that inspire and delight our customers around the world." Said Maurizio Volpi, President Fragrance & Beauty.
"Encapsulation is one of the most transformative technologies in our field. By combining Givaudan's deep expertise in fragrance creation and innovation, and our commitment to collaborate with Microcaps' breakthrough technologies, we can explore new ways to enhance performance and sustainability for consumers across many fragrance and skincare applications." Said Jeremy Compton, Global Head of Science & Technology Fragrances
The collaboration also marks an exciting milestone for Microcaps. Dr Alessandro Ofner and Michael Hagander, founders and Co-CEOs of Microcaps, commented:
"We are thrilled to join forces with Givaudan, the global leader in fragrance and beauty. This collaboration allows us to scale our technology and bring scientific precision to a wider market. Working together with Givaudan opens new doors for innovation. Together, we can redefine what high precision encapsulation means for the fragrance and beauty industries."
Through this collaboration, Givaudan reaffirms its commitment to novelty, excellence, and leadership, captivating another step in shaping the future of fragrances and cosmetics.
According to Towards Healthcare, the microfluidic drug delivery technologies market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 3.65 billion in 2026 to approximately USD 12.64 billion by 2035, representing a compound annual growth rate (CAGR) of 14.8% from 2026 to 2035, driven by microfluidic technology, which allows the development of carrier-free drug delivery technology.
By leveraging the accuracy and control offered by microfluidic platforms, drugs delivered directly to particular sites, reducing the requirement for conventional therapeutic carriers. Microfluidic channels enable for the continuous, skillful synthesis of lipid-based and polymeric nanoparticles. This produces extensively uniform, monodisperse carriers with advanced encapsulation effectiveness and tunable release profiles. Microfluidic 3D platforms recreate in vivo organ and cell environments on a chip, enabling highly precise, high-throughput drug toxicity and effectiveness testing without instant reliance on animal models.
forwarded from Givaudan and Microcaps Partner to Advance Fragrance Innovation